DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,871 filers reported holding DANAHER CORPORATION in Q3 2021. The put-call ratio across all filers is 1.50 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $58,051,911 | +13.0% | 263,976 | +23.4% | 0.42% | +19.3% |
| Q2 2023 | $51,352,395 | +9.4% | 213,968 | +14.9% | 0.35% | +2.6% |
| Q1 2023 | $46,956,025 | -3.3% | 186,301 | +1.8% | 0.34% | -8.0% |
| Q4 2022 | $48,555,303 | +4.9% | 182,934 | +2.0% | 0.37% | -0.5% |
| Q3 2022 | $46,306,000 | +4.7% | 179,281 | +2.8% | 0.38% | +14.0% |
| Q2 2022 | $44,220,000 | -10.1% | 174,424 | +4.0% | 0.33% | +5.4% |
| Q1 2022 | $49,187,000 | -12.0% | 167,684 | -1.3% | 0.31% | -15.0% |
| Q4 2021 | $55,907,000 | +13.9% | 169,927 | +5.4% | 0.37% | +2.8% |
| Q3 2021 | $49,086,000 | +25.0% | 161,234 | +10.2% | 0.36% | +24.4% |
| Q2 2021 | $39,261,000 | +36.1% | 146,299 | +14.1% | 0.29% | +22.6% |
| Q1 2021 | $28,848,000 | +3.2% | 128,168 | +1.9% | 0.23% | -8.9% |
| Q4 2020 | $27,948,000 | -5.8% | 125,813 | -8.7% | 0.26% | -19.9% |
| Q3 2020 | $29,663,000 | +24.1% | 137,756 | +2.0% | 0.32% | -3.9% |
| Q2 2020 | $23,899,000 | +28.1% | 135,106 | +0.2% | 0.33% | +28.5% |
| Q1 2020 | $18,655,000 | -15.2% | 134,782 | -5.9% | 0.26% | +6.6% |
| Q4 2019 | $21,986,000 | +22.0% | 143,229 | +14.8% | 0.24% | +15.1% |
| Q3 2019 | $18,026,000 | +20.1% | 124,809 | +18.8% | 0.21% | +15.8% |
| Q2 2019 | $15,015,000 | +45.6% | 105,059 | +34.5% | 0.18% | +37.6% |
| Q1 2019 | $10,312,000 | +49.2% | 78,124 | +16.5% | 0.13% | +30.4% |
| Q4 2018 | $6,912,000 | +5.3% | 67,032 | +11.0% | 0.10% | +22.9% |
| Q3 2018 | $6,563,000 | +19.2% | 60,395 | +6.9% | 0.08% | +7.8% |
| Q2 2018 | $5,505,000 | +0.5% | 56,522 | +1.0% | 0.08% | +1.3% |
| Q1 2018 | $5,477,000 | +33.3% | 55,943 | +26.3% | 0.08% | +38.2% |
| Q4 2017 | $4,110,000 | +54.5% | 44,278 | +42.7% | 0.06% | +44.7% |
| Q3 2017 | $2,661,000 | +100.5% | 31,033 | +97.3% | 0.04% | +72.7% |
| Q2 2017 | $1,327,000 | -7.2% | 15,731 | -5.8% | 0.02% | -8.3% |
| Q1 2017 | $1,430,000 | +12.5% | 16,701 | +2.3% | 0.02% | +20.0% |
| Q4 2016 | $1,271,000 | -80.8% | 16,325 | -80.7% | 0.02% | -83.6% |
| Q3 2016 | $6,614,000 | +386.3% | 84,473 | +527.4% | 0.12% | +335.7% |
| Q2 2016 | $1,360,000 | +8.7% | 13,464 | +2.1% | 0.03% | +3.7% |
| Q1 2016 | $1,251,000 | +17.4% | 13,184 | +14.9% | 0.03% | +12.5% |
| Q4 2015 | $1,066,000 | +9.1% | 11,474 | 0.0% | 0.02% | +9.1% |
| Q3 2015 | $977,000 | +20.0% | 11,474 | +19.1% | 0.02% | +37.5% |
| Q2 2015 | $814,000 | +276.9% | 9,634 | +278.5% | 0.02% | +166.7% |
| Q1 2015 | $216,000 | – | 2,545 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |